Printed from:

Welcome to Columbia Magazine  

KY Ag settlement secures $152,000 for state general fund

Boehringer Ingelheim allegedly falsified benefits of its prescription drugs. Beshear's office has returned nearly $6 million to the state's general fund in 2017 through civil litigation and settlements.
Click on headline for complete story

By Terry Sebastian or Crystal Staley
News from the office of KY Attorney General Andy Beshear

FRANKFORT, KY (20 Dec 2017) - Attorney General Andy Beshear announced today his office secured $152,000 for the state's General Fund from a settlement with a Connecticut-based pharmaceutical company for improperly promoting its drugs to Kentuckians.

The multi-million dollar nationwide multistate settlement resolves allegations Boehringer Ingelheim Pharmaceuticals Inc. engaged in off-label marketing and made deceptive and misleading representations in its promotion of four of its prescription drugs used to prevent stroke, COPD and hypertension.

"Kentuckians are being ripped off every single day," Beshear said. "My office is taking a stand. We will hold anyone accountable who misrepresents their products."

The settlement alleges the company:
  • Misrepresented that its antiplatelet drug, Aggrenox(R), was effective for many conditions "below the neck," such as heart attacks and congestive heart failure, and that it was superior to Plavix(R) without evidence to substantiate that claim
  • Misrepresented that Micardis(R) protected patients from early morning strokes and heart attacks and treated metabolic syndrome
  • Misrepresented that Combivent(R) could be used as a first-line treatment for bronchospasms associated with chronic obstructive pulmonary disease (COPD); and
  • Falsely stated that Atrovent(R) and Combivent(R) could be used at doses that exceeded the maximum dosage recommendation in the product labeling and that the drugs were essential for treatment of COPD
The settlement requires Boehringer Ingelheim to ensure that its marketing and promotional practices do not unlawfully promote these prescription drug products. For example, the agreement ensures clinically relevant information is provided in an unbiased manner that is distinct from promotional materials.

Beshear's office has returned nearly $6 million to the state's general fund in 2017 through civil litigation and settlements.

This story was posted on 2017-12-21 06:05:39
Printable: this page is now automatically formatted for printing.
Have comments or corrections for this story? Use our contact form and let us know.


Quick Links to Popular Features

Looking for a story or picture?
Try our Photo Archive or our Stories Archive for all the information that's appeared on


Contact us: Columbia Magazine and are published by D'Zine, Ltd., PO Box 906, Columbia, KY 42728.
Phone: 270.403.0017

Please use our contact page, or send questions about technical issues with this site to All logos and trademarks used on this site are property of their respective owners. All comments remain the property and responsibility of their posters, all articles and photos remain the property of their creators, and all the rest is copyright 1995-Present by Columbia! Magazine and D'Zine, Ltd. Privacy policy: use of this site requires no sharing of information. Voluntarily shared information may be published and made available to the public on this site and/or stored electronically. Anonymous submissions will be subject to additional verification. Cookies are not required to use our site. However, if you have cookies enabled in your web browser, some of our advertisers may use cookies for interest-based advertising across multiple domains. For more information about third-party advertising, visit the NAI web privacy site.